US20220144817A1 - Compounds and methods of deuterated xanomeline for treating neurological disorders - Google Patents

Compounds and methods of deuterated xanomeline for treating neurological disorders Download PDF

Info

Publication number
US20220144817A1
US20220144817A1 US17/310,735 US202017310735A US2022144817A1 US 20220144817 A1 US20220144817 A1 US 20220144817A1 US 202017310735 A US202017310735 A US 202017310735A US 2022144817 A1 US2022144817 A1 US 2022144817A1
Authority
US
United States
Prior art keywords
compound
medicament
milligrams
trospium chloride
xanomeline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/310,735
Other languages
English (en)
Inventor
Dennis Bennett
Giorgio Attardo
Clifford Schlecht
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karuna Therapeutics Inc
Original Assignee
Karuna Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karuna Therapeutics Inc filed Critical Karuna Therapeutics Inc
Priority to US17/310,735 priority Critical patent/US20220144817A1/en
Assigned to Karuna Therapeutics, Inc. reassignment Karuna Therapeutics, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ATTARDO, GIORGIO, BENNETT, DENNIS, SCHLECHT, Clifford
Publication of US20220144817A1 publication Critical patent/US20220144817A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • the present disclosure relates to new compounds and compositions, and their application as pharmaceuticals for treating disease.
  • Methods of treating neurological disorders, such as psychosis and schizophrenia, in a human or animal subject are also provided.
  • Xanomeline [3-(hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole] is a mixed muscarinic partial agonist across all five muscarinic receptor subtypes:
  • Activating the muscarinic system through muscarinic agonists may treat several diseases, including schizophrenia, Alzheimer's disease, Parkinson's disease, depression, movement disorders, drug addiction. pain, and neurodegeneration, such as tauopathies or synucleinopathies.
  • Schizophrenia is characterized by a set of symptoms divided into positive symptoms (e.g., hallucinations, delusional thoughts, etc.), negative symptoms (e.g., social isolation, anhedonia, etc.), and cognitive symptoms (e.g., inability to process information, poor working memory, etc.
  • positive symptoms e.g., hallucinations, delusional thoughts, etc.
  • negative symptoms e.g., social isolation, anhedonia, etc.
  • cognitive symptoms e.g., inability to process information, poor working memory, etc.
  • the metabolic profile in humans and lack of muscarinic receptor subtype selectivity has been problematic for the development of this drug.
  • xanomeline was reformulated as xanome
  • certain compounds disclosed herein provide deuterated xanomeline with improved pharmacokinetics (PK), pharmacodynamics (PD), and toxicity profiles. Using these compounds reduces drug exposure variability and the incidence of metabolites. Without wishing to be bound by theory, first-pass metabolism is avoided via deuteration of xanomeline at carbon positions susceptible to cytochrome p-450 mediated enzymatic oxidation.
  • the compound comprises Formula II
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are independently chosen from H and D;
  • R is CH 3 or CD 3 ; and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , or R 13 is enriched with deuterium.
  • the compound comprises Formula III
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 19 , R 20 , and R 21 are independently chosen from H or D.
  • the compound comprises Formula IV
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 19 , R 20 , and R 21 are independently chosen from H or D.
  • the compound comprises Formula V
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 19 , R 20 , and R 21 are independently chosen from H or D.
  • the compound comprises Formula VI
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 19 , R 20 , and R 21 are independently chosen from H or D.
  • the compound comprises Formula VII
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 19 , R 20 , and R 21 are independently chosen from H or D.
  • the compound comprises Formula VIII
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 19 , R 20 , and R 21 are independently chosen from H or D.
  • FIG. 1 depicts the normalized xanomeline concentration in pg/mg versus time in hours for rats dosed with xanomeline tartrate, xanomeline-d 13 tartrate and xanomeline-d 16 tartrate. Doses were normalized to actual dosing concentration in mg/mL.
  • FIG. 2 depicts the [ 3 H]-NMS specific binding ( ⁇ 14 nM) in CHO cells measured in counts per minute activity (CPMA).
  • FIG. 3 depicts the [ 3 H]-NMS specific binding ( ⁇ 14 nM) in CHO cells from FIG. 2 normalized to femtomoles per milligram protein (fmol/mg).
  • any of the listed items can be employed by itself or in combination with one or more of the listed items.
  • the expression “A and/or B” means either or both of A and B, i.e. A alone, B alone or A and B in combination.
  • the expression “A, B and/or C” is intended to mean A alone, B alone, C alone, A and B in combination, A and C in combination, B and C in combination or A, B, and C in combination.
  • deuterium enrichment refers to the percentage of incorporation of deuterium at a given position in a molecule in the place of hydrogen. For example, deuterium enrichment of 1% at a given position means that 1% of molecules in a given sample contain deuterium at the specified position. Because the naturally occurring distribution of deuterium is about 0.0156%, deuterium enrichment at any position in a compound synthesized using non-enriched starting materials is about 0.0156%. The deuterium enrichment can be determined using conventional analytical methods, such as mass spectrometry and nuclear magnetic resonance spectroscopy.
  • deuterium when used to describe a given position in a molecule such as R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 5 , R 9 , R 10 , and R 11 or the symbol “D,” when used to represent a given position in a drawing of a molecular structure, means that the specified position is enriched with deuterium above the naturally occurring distribution of deuterium.
  • deuterium enrichment is of no less than about 1%, in another no less than about 5%, in another no less than about 10%, in another no less than about 20%, in another no less than about 50%, in another no less than about 70%, in another no less than about 80%, in another no less than about 90%, or in another no less than about 98% of deuterium at the specified position.
  • isotopic enrichment refers to the percentage of incorporation of a less prevalent isotope of an element at a given position in a molecule in the place of the more prevalent isotope of the element.
  • non-isotopically enriched refers to a molecule in which the percentages of the various isotopes are substantially the same as the naturally occurring percentages.
  • substantially pure and substantially homogeneous mean sufficiently homogeneous to appear free of readily detectable impurities as determined by standard analytical methods, including, but not limited to, thin layer chromatography (TLC), gel electrophoresis, high performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), and mass spectrometry (MS); or sufficiently pure such that further purification would not detectably alter the physical and chemical properties, or biological and pharmacological properties, such as enzymatic and biological activities, of the substance.
  • TLC thin layer chromatography
  • HPLC high performance liquid chromatography
  • NMR nuclear magnetic resonance
  • MS mass spectrometry
  • substantially pure or substantially homogeneous refers to a collection of molecules, wherein at least about 50%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 98%, at least about 99%, or at least about 99.5% of the molecules are a single compound, including a racemic mixture or single stereoisomer thereof, as determined by standard analytical methods.
  • R or the term R′ refers to a moiety chosen from hydrogen, alkyl, cycloalkyl, heteroalkyl, aryl, heteroaryl and heterocycloalkyl, any of which is optionally substituted.
  • aryl, heterocycle, R, etc. occur more than one time in a formula or generic structure, its definition at each occurrence is independent of the definition at every other occurrence.
  • certain groups may be attached to a parent molecule or may occupy a position in a chain of elements from either end as written.
  • an unsymmetrical group such as —C(O)N(R)— may be attached to the parent moiety at either the carbon or the nitrogen.
  • disease as used herein is intended to be generally synonymous, and is used interchangeably with, the terms “disorder,” “syndrome,” and “condition” (as in medical condition), in that all reflect an abnormal condition of the human or animal body or of one of its parts that impairs normal functioning, is typically manifested by distinguishing signs and symptoms, and causes the human or animal to have a reduced duration or quality of life.
  • combination therapy means the administration of two or more therapeutic agents to treat a therapeutic condition or disorder described in the present disclosure. Such administration encompasses co-administration of these therapeutic agents in a substantially simultaneous manner, such as in a single dosage having a fixed ratio of active ingredients or in multiple, separate capsules for each active ingredient. In addition, such administration also encompasses use of each type of therapeutic agent in a sequential manner. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
  • terapéuticaally effective is intended to qualify the amount of active ingredients used in the treating a disease or disorder or on the effecting of a clinical endpoint.
  • terapéuticaally acceptable refers to those compounds (or salts, prodrugs, tautomers, zwitterionic forms, etc.) suitable for use in contact with the tissues of patients without undue toxicity, irritation, and allergic response, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
  • treatment of a patient is intended to include prophylaxis. Treatment may also be preemptive in nature, i.e., it may include prevention of disease. Prevention of a disease may involve complete protection from disease, for example as in the case of prevention of infection with a pathogen or may involve prevention of disease progression. For example, prevention of a disease may not mean complete foreclosure of any effect related to the diseases at any level, but instead may mean prevention of the symptoms of a disease to a clinically significant or detectable level. Prevention of diseases may also mean prevention of progression of a disease to a later stage of the disease.
  • patient is generally synonymous with the term “subject” and includes all mammals including humans. Examples of patients include humans, livestock such as cows, goats, sheep, pigs, and rabbits, and companion animals such as dogs, cats, rabbits, and horses. Preferably, the patient is a human.
  • prodrug refers to a compound that is made more active in vivo. Certain compounds disclosed herein may also exist as prodrugs. Prodrugs of the compounds described herein are structurally modified forms of the compound that readily undergo chemical changes under physiological conditions to provide the compound. Additionally, prodrugs can be converted to the compound by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to a compound when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because, in some situations, they may be easier to administer than the compound, or parent drug. They may, for instance, be bioavailable by oral administration whereas the parent drug is not. The prodrug may also have improved solubility in pharmaceutical compositions over the parent drug.
  • prodrug derivatives are known in the art, such as those that rely on hydrolytic cleavage or oxidative activation of the prodrug.
  • An example, without limitation, of a prodrug would be a compound which is administered as an ester (the “prodrug”), but then is metabolically hydrolyzed to the carboxylic acid, the active entity. Additional examples include peptidyl derivatives of a compound.
  • the animal body expresses various enzymes, such as the cytochrome P 450 enzymes or CYPs, esterases, proteases, reductases, dehydrogenases, and monoamine oxidases, to react with and convert these foreign substances to more polar intermediates or metabolites for renal excretion.
  • enzymes such as the cytochrome P 450 enzymes or CYPs, esterases, proteases, reductases, dehydrogenases, and monoamine oxidases.
  • the resultant metabolites may be stable or unstable under physiological conditions, and can have substantially different pharmacokinetic, pharmacodynamic, and acute and long-term toxicity profiles relative to the parent compounds. For most drugs, such oxidations are generally rapid and ultimately lead to administration of multiple or high daily doses.
  • the Arrhenius equation states that the fraction of molecules that have enough energy to overcome an energy barrier, that is, those with energy at least equal to the activation energy, depends exponentially on the ratio of the activation energy to thermal energy (RT), the average amount of thermal energy that molecules possess at a certain temperature.
  • the transition state in a reaction is a short-lived state (on the order of 10 ⁇ 14 sec) along the reaction pathway during which the original bonds have stretched to their limit.
  • the activation energy E act for a reaction is the energy required to reach the transition state of that reaction. Reactions that involve multiple steps will necessarily have several transition states, and in these instances, the activation energy for the reaction is equal to the energy difference between the reactants and the most unstable transition state. Once the transition state is reached, the molecules can either revert, thus reforming the original reactants, or the new bonds form giving rise to the products. This dichotomy is possible because both pathways, forward and reverse, result in the release of energy.
  • a catalyst facilitates a reaction process by lowering the activation energy leading to a transition state. Enzymes are examples of biological catalysts that reduce the energy necessary to achieve a transition state.
  • a carbon-hydrogen bond is by nature a covalent chemical bond. Such a bond forms when two atoms of similar electronegativity share some of their valence electrons, thereby creating a force that holds the atoms together. This force or bond strength can be quantified and is expressed in units of energy, and as such, covalent bonds between various atoms can be classified according to how much energy must be applied to the bond in order to break the bond or separate the two atoms.
  • the bond strength is directly proportional to the absolute value of the ground-state vibrational energy of the bond.
  • This vibrational energy which is also known as the zero-point vibrational energy, depends on the mass of the atoms that form the bond.
  • the absolute value of the zero-point vibrational energy increases as the mass of one or both atoms making the bond increases. Since deuterium (D) is two-fold more massive than hydrogen (H), it follows that a C-D bond is stronger than the corresponding C—H bond.
  • Compounds with C-D bonds are frequently indefinitely stable in H 2 O and have been widely used for isotopic studies. If a C—H bond is broken during a rate-determining step in a chemical reaction (i.e.
  • DKIE Deuterium Kinetic Isotope Effect
  • High DKIE values may be due in part to a phenomenon known as tunneling, which is a consequence of the uncertainty principle. Tunneling is ascribed to the small size of a hydrogen atom and occurs because transition states involving a proton can sometimes form in the absence of the required activation energy. A deuterium is larger and statistically has a much lower probability of undergoing this phenomenon. Substitution of tritium for hydrogen results in yet a stronger bond than deuterium and gives numerically larger isotope effects.
  • deuterium is a stable and non-radioactive isotope of hydrogen. It was the first isotope to be separated from its element in pure form and is twice as massive as hydrogen and makes up about 0.02% of the total mass of hydrogen (in this usage meaning all hydrogen isotopes) on earth.
  • deuterium oxide D 2 O or “heavy water”
  • D 2 O looks and tastes like H 2 O, but has different physical properties. It boils at 101.41° C. and freezes at 3.79° C. Its heat capacity, heat of fusion, heat of vaporization, and entropy are all higher than H 2 O. It is also more viscous and is not as powerful a solvent as H 2 O.
  • the animals also become very aggressive; males becoming almost unmanageable. When about 30%, of the body water has been replaced with D 2 O, the animals refuse to eat and become comatose. Their body weight drops sharply, and their metabolic rates drop far below normal, with death occurring at about 30 to about 35% replacement with D 2 O. The effects are reversible unless more than thirty percent of the previous body weight has been lost due to D 2 O. Studies have also shown that the use of D 2 O can delay the growth of cancer cells and enhance the cytotoxicity of certain antineoplastic agents.
  • Tritium is a radioactive isotope of hydrogen, used in research, fusion reactors, neutron generators and radiopharmaceuticals. Mixing tritium with a phosphor provides a continuous light source, a technique that is commonly used in wristwatches, compasses, rifle sights and exit signs. It was discovered by Rutherford, Oliphant and Harteck in 1934, and is produced naturally in the upper atmosphere when cosmic rays react with H 2 molecules. Tritium is a hydrogen atom that has 2 neutrons in the nucleus and has an atomic weight close to 3. It occurs naturally in the environment in very low concentrations, most commonly found as T 2 O, a colorless and odorless liquid.
  • PK pharmacokinetics
  • PD pharmacodynamics
  • toxicity profiles have been demonstrated previously with some classes of drugs.
  • DKIE was used to decrease the hepatotoxicity of halothane by presumably limiting the production of reactive species such as trifluoroacetyl chloride.
  • this method may not be applicable to all drug classes.
  • deuterium incorporation can lead to metabolic switching which may even give rise to an oxidative intermediate with a faster off-rate from an activating Phase I enzyme (e.g., cytochrome P 450 3A4).
  • Xanomeline is a functionally selective M1/M4 agonist that has shown a promising therapeutic profile in preclinical trials (Shannon et al., 1994)
  • the carbon-hydrogen bonds of xanomeline contain a naturally occurring distribution of hydrogen isotopes, namely 1 H or protium (about 99.9844%), 2 H or deuterium (about 0.0156%), and 3 H or tritium (in the range between about 0.5 and 67 tritium atoms per 10 18 protium atoms).
  • KIE Kinetic Isotope Effect
  • Xanomeline is likely metabolized in humans by liver (Nicholas D et al., 2001). Other sites on the molecule may also undergo transformations leading to metabolites with as-yet-unknown pharmacology/toxicology. Limiting the production of these metabolites has the potential to decrease the danger of the administration of such drugs and may even allow increased dosage and concomitant increased efficacy. All these transformations can occur through polymorphically-expressed enzymes, thus exacerbating the interpatient variability. Further, disorders, such as multiple sclerosis, are best treated when the subject is medicated around the clock for an extended period. For the foregoing reasons, there is a strong likelihood that a longer half-life medicine will diminish these problems with greater efficacy and cost savings.
  • Various deuteration patterns can be used to a) reduce or eliminate unwanted metabolites, b) increase the half-life of the parent drug, c) decrease the number of doses needed to achieve a desired effect, d) decrease the amount of a dose needed to achieve a desired effect, e) increase the formation of active metabolites, if any are formed, and/or f) decrease the production of deleterious metabolites in specific tissues and/or create a more effective drug and/or a safer drug for polypharmacy, whether the polypharmacy be intentional or not.
  • the deuteration approach has strong potential to slow the metabolism via various oxidative and racemization mechanisms.
  • the compound comprises f Formula II
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , and R 13 are independently chosen from H and D;
  • R is CH 3 or CD 3 ; and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , or R 13 is enriched with deuterium.
  • the compound comprises Formula IIA
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are independently chosen from H and D;
  • R is CH 3 or CD 3 ; and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 is enriched with deuterium.
  • the compound comprises Formula IIB
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are independently chosen from H and D;
  • R is CH 3 or CD 3 ; and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 is enriched with deuterium.
  • the compound comprises Formula IIC
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are independently chosen from H and D;
  • R is CH 3 or CD 3 ; and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 is enriched with deuterium.
  • the compound is chosen from:
  • the compound is chosen from:
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each D, and R is CH 3 .
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each D, and R is CD 3 .
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are each D, and R is CH 3 .
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 and R 11 are each D, and R is CD 3 .
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each D, and R is CH 3 .
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are each D, and R is CD 3 .
  • R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each D, and R is CH 3 . In certain embodiments, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are each D, and R is CD 3 . In certain embodiments, R 1 , R 2 , R 3 , R 4 and R 5 are each D, and R is CH 3 .
  • R 1 , R 2 , R 3 , R 4 and R 5 are each D, and R is CD 3 .
  • R 1 , R 2 and R 3 are each D, and R is CH 3 .
  • R 1 , R 2 and R 3 are each D, and R is CD 3 .
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each D, and R is CH 3 .
  • R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R are each D, and R is CD 3 .
  • R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each D, and R is CH 3 . In certain embodiments, R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each D, and R is CD 3 . In certain embodiments, R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each D, and R is CH 3 . In certain embodiments, R 8 , R 9 , R 10 , R 11 , R 12 and R 13 are each D, and R is CD 3 .
  • R 10 , R 11 , R 12 and R 13 are each D, and R is CH 3 . In certain embodiments, R 10 , R 11 , R 12 and R 13 are each D, and R is CD 3 . In certain embodiments, R 12 and R 13 are each D, and R is CH 3 . In certain embodiments, R 12 and R 13 are each D, and R is CD 3 .
  • R 4 and R 5 are each D, and R is CH 3 . In certain embodiments, R 4 and R 5 are each D, and R is CD 3 . In certain embodiments, R 6 and R 7 are each D, and R is CH 3 . In certain embodiments, R 6 and R 7 are each D, and R is CD 3 . In certain embodiments, R 8 and R 9 are each D, and R is CH 3 . In certain embodiments, R 8 and R 9 are each D, and R is CD 3 . In certain embodiments, R 10 and R 11 are each D, and R is CH 3 . In certain embodiments, R 10 and R 11 are each D, and R is CD 3 .
  • the compound comprises Formula III
  • the compound is chosen from:
  • the compound comprises Formula IV
  • the compound is chosen from:
  • the compound comprises Formula V
  • the compound is chosen from:
  • the compound comprises Formula VI
  • the compound is chosen from:
  • the compound comprises Formula VII
  • the compound is chosen from:
  • the compound comprises Formula VIII
  • the compound is chosen from:
  • the present disclosure also provides a method of treating a central nervous system disorder in a patient in need thereof, the method comprising administrating therapeutically effective amount of a medicament described herein to the patient in need thereof.
  • the medicament is orally administered.
  • use of the trospium chloride when present, alleviates a side effect associated with use of a compound or composition described herein.
  • At least one of the positions represented as D independently has deuterium enrichment of no less than about 1%, no less than about 5%, no less than about 10%, no less than about 20%, no less than about 50%, no less than about 70%, no less than about 80%, no less than about 90%, or no less than about 98%.
  • said compound is substantially a single enantiomer, a mixture of about 90% or more by weight of the ( ⁇ )-enantiomer and about 10% or less by weight of the (+)-enantiomer, a mixture of about 90% or more by weight of the (+)-enantiomer and about 10% or less by weight of the ( ⁇ )-enantiomer, substantially an individual diastereomer, or a mixture of about 90% or more by weight of an individual diastereomer and about 10% or less by weight of any other diastereomer.
  • the compound as disclosed herein contains about 60% or more by weight of the ( ⁇ )-enantiomer of the compound and about 40% or less by weight of (+)-enantiomer of the compound. In certain embodiments, the compound as disclosed herein contains about 70% or more by weight of the ( ⁇ )-enantiomer of the compound and about 30% or less by weight of (+)-enantiomer of the compound. In certain embodiments, the compound as disclosed herein contains about 80% or more by weight of the ( ⁇ )-enantiomer of the compound and about 20% or less by weight of (+)-enantiomer of the compound.
  • the compound as disclosed herein contains about 90% or more by weight of the ( ⁇ )-enantiomer of the compound and about 10% or less by weight of the (+)-enantiomer of the compound. In certain embodiments, the compound as disclosed herein contains about 95% or more by weight of the ( ⁇ )-enantiomer of the compound and about 5% or less by weight of (+)-enantiomer of the compound. In certain embodiments, the compound as disclosed herein contains about 99% or more by weight of the ( ⁇ )-enantiomer of the compound and about 1% or less by weight of (+)-enantiomer of the compound.
  • the compound as disclosed herein contains about 60% or more by weight of the (+)-enantiomer of the compound and about 40% or less by weight of ( ⁇ )-enantiomer of the compound. In certain embodiments, the compound as disclosed herein contains about 70% or more by weight of the (+)-enantiomer of the compound and about 30% or less by weight of ( ⁇ )-enantiomer of the compound. In certain embodiments, the compound as disclosed herein contains about 80% or more by weight of the (+)-enantiomer of the compound and about 20% or less by weight of ( ⁇ )-enantiomer of the compound.
  • the compound as disclosed herein contains about 90% or more by weight of the (+)-enantiomer of the compound and about 10% or less by weight of the ( ⁇ )-enantiomer of the compound. In certain embodiments, the compound as disclosed herein contains about 95% or more by weight of the (+)-enantiomer of the compound and about 5% or less by weight of ( ⁇ )-enantiomer of the compound. In certain embodiments, the compound as disclosed herein contains about 99% or more by weight of the (+)-enantiomer of the compound and about 1% or less by weight of ( ⁇ )-enantiomer of the compound.
  • the deuterated compound as disclosed herein may also contain less prevalent isotopes for other elements, including, but not limited to, 13 C or 14 C for carbon, 15 N for nitrogen, and 17 O or 18 O for oxygen.
  • the deuterated compounds disclosed herein maintain the beneficial aspects of the corresponding non-isotopically enriched molecules while substantially increasing the maximum tolerated dose, decreasing toxicity, increasing the half-life (T 1/2 ), lowering the maximum plasma concentration (C max ) of the minimum efficacious dose (MED), lowering the efficacious dose and thus decreasing the non-mechanism-related toxicity, and/or lowering the probability of drug-drug interactions.
  • Isotopic hydrogen can be introduced into a compound of a compound disclosed herein as disclosed herein by synthetic techniques that employ deuterated reagents, whereby incorporation rates are pre-determined; and/or by exchange techniques, wherein incorporation rates are determined by equilibrium conditions, and may be highly variable depending on the reaction conditions.
  • Synthetic techniques where tritium or deuterium is directly and specifically inserted by tritiated or deuterated reagents of known isotopic content, may yield high tritium or deuterium abundance, but can be limited by the chemistry required.
  • the molecule being labeled may be changed, depending upon the severity of the synthetic reaction employed.
  • Isotopic hydrogen can be introduced into organic molecules by synthetic techniques that employ deuterated reagents whereby incorporation rates are pre-determined and/or by exchange techniques wherein incorporation rates are determined by equilibrium conditions and may be highly variable depending on the reaction conditions. Synthetic techniques, where tritium or deuterium is directly and specifically inserted by tritiated or deuterated reagents of known isotopic content, may yield high tritium or deuterium abundance, but can be limited by the chemistry required. In addition, the molecule being labeled may be changed, depending upon the severity of the synthetic reaction employed.
  • the compounds disclosed herein may contain one or more chiral centers, chiral axes, and/or chiral planes, as described in “Stereochemistry of Carbon Compounds” Eliel and Wilen, John Wiley & Sons, New York, 1994, pp. 1119-1190.
  • Such chiral centers, chiral axes, and chiral planes may be of either the (R) or (S) configuration or may be a mixture thereof.
  • Another method for characterizing a composition containing a compound having at least one chiral center is by the effect of the composition on a beam of polarized light.
  • a beam of plane polarized light is passed through a solution of a chiral compound, the plane of polarization of the light that emerges is rotated relative to the original plane.
  • This phenomenon is known as optical activity, and compounds that rotate the plane of polarized light are said to be optically active.
  • One enantiomer of a compound will rotate the beam of polarized light in one direction, and the other enantiomer will rotate the beam of light in the opposite direction.
  • compositions described herein include compositions containing between 0 and 100% of the (+) and/or ( ⁇ ) enantiomer of compounds disclosed herein.
  • a compound as disclosed herein contains an alkenyl or alkenylene group
  • the compound may exist as one or mixture of geometric cis/trans (or Z/E) isomers.
  • structural isomers are interconvertible via a low energy barrier
  • the compound disclosed herein may exist as a single tautomer or a mixture of tautomers. This can take the form of proton tautomerism in the compound disclosed herein that contains for example, an imino, keto, or oxime group; or so-called valence tautomerism in the compound that contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.
  • the compounds disclosed herein may be enantiomerically pure, such as a single enantiomer or a single diastereomer, or be stereoisomeric mixtures, such as a mixture of enantiomers, a racemic mixture, or a diastereomeric mixture.
  • administration of a compound in its (R) form is equivalent, for compounds that undergo epimerization in vivo, to administration of the compound in its (S) form.
  • the compounds disclosed herein can exist as therapeutically acceptable salts.
  • the present disclosure includes compounds listed above in the form of salts, including acid addition salts. Suitable salts include those formed with both organic and inorganic acids. Such acid addition salts will normally be pharmaceutically acceptable. However, salts of non-pharmaceutically acceptable salts may be of utility in the preparation and purification of the compound in question. Basic addition salts may also be formed and be pharmaceutically acceptable.
  • terapéuticaally acceptable salt represents salts or zwitterionic forms of the compounds disclosed herein which are water or oil-soluble or dispersible and therapeutically acceptable as defined herein.
  • the salts can be prepared during the final isolation and purification of the compounds or separately by reacting the appropriate compound in the form of the free base with a suitable acid.
  • Representative acid addition salts include acetate, adipate, alginate, L-ascorbate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsulfonate, citrate, digluconate, formate, fumarate, gentisate, glutarate, glycerophosphate, glycolate, hemisulfate, heptanoate, hexanoate, hippurate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, malonate, DL-mandelate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenyl
  • basic groups in the compounds disclosed herein can be quaternized with methyl, ethyl, propyl, and butyl chlorides, bromides, and iodides; dimethyl, diethyl, dibutyl, and diamyl sulfates; decyl, lauryl, myristyl, and steryl chlorides, bromides, and iodides; and benzyl and phenethyl bromides.
  • acids which can be employed to form therapeutically acceptable addition salts include inorganic acids such as hydrochloric, hydrobromic, sulfuric, and phosphoric, and organic acids such as oxalic, maleic, succinic, and citric. Salts can also be formed by coordination of the compounds with an alkali metal or alkaline earth ion.
  • the present disclosure contemplates sodium, potassium, magnesium, and calcium salts of the compounds disclosed herein, and the like.
  • Basic addition salts can be prepared during the final isolation and purification of the compounds by reacting a carboxy group with a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • a suitable base such as the hydroxide, carbonate, or bicarbonate of a metal cation or with ammonia or an organic primary, secondary, or tertiary amine.
  • the cations of therapeutically acceptable salts include lithium, sodium, potassium, calcium, magnesium, and aluminum, as well as nontoxic quaternary amine cations such as ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine, tributylamine, pyridine, N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine, dicyclohexylamine, procaine, dibenzylamine, N,N-dibenzylphenethylamine, 1-ephenamine, and N,N-dibenzylethylenediamine.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, and piperazine.
  • a salt of a compound can be made by reacting the appropriate compound in the form of the free base with the appropriate acid.
  • the compound as disclosed herein may also be designed as a prodrug, which is a functional derivative of the compound as disclosed herein and is readily convertible into the parent compound in vivo.
  • Prodrugs are often useful because, in some situations, they may be easier to administer than the parent compound. They may, for instance, be bioavailable by oral administration whereas the parent compound is not.
  • the prodrug may also have enhanced solubility in pharmaceutical compositions over the parent compound.
  • a prodrug may be converted into the parent drug by various mechanisms, including enzymatic processes and metabolic hydrolysis. See Harper, Progress in Drug Research 1962, 4, 221-294; Morozowich et al. in “Design of Biopharmaceutical Properties through Prodrugs and Analogs,” Roche Ed., APHA Acad. Pharm. Sci.
  • compositions which comprise one or more of certain compounds disclosed herein, or one or more pharmaceutically acceptable salts, esters, prodrugs, amides, or solvates thereof, together with one or more pharmaceutically acceptable carriers thereof and optionally one or more other therapeutic ingredients.
  • the carrier(s) must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Proper formulation is dependent upon the route of administration chosen. Any of the well-known techniques, carriers, and excipients may be used as suitable and as understood in the art.
  • compositions disclosed herein may be manufactured in any manner known in the art, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compression processes.
  • the formulations include those suitable for oral, parenteral (including subcutaneous, intradermal, intramuscular, intravenous, intraarticular, and intramedullary), intraperitoneal, transmucosal, transdermal, rectal and topical (including dermal, buccal, sublingual and intraocular) administration although the most suitable route may depend upon for example the condition and disorder of the recipient.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Typically, these methods include the step of bringing into association a compound disclosed herein or a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof (“active ingredient”) with the carrier which constitutes one or more accessory ingredients.
  • active ingredient a pharmaceutically acceptable salt, ester, amide, prodrug or solvate thereof
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • Formulations of the compounds disclosed herein suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • compositions which can be used orally include tablets, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. Tablets may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with binders, inert diluents, or lubricating, surface active or dispersing agents. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
  • the tablets may optionally be coated or scored and may be formulated to provide slow or controlled release of the active ingredient therein. All formulations for oral administration should be in dosages suitable for such administration.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • Dragee cores are provided with suitable coatings.
  • concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, Carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • a single dosage form contains 50 mg xanomeline as the tartrate salt and 10 mg trospium chloride. Because 50 mg xanomeline as free base corresponds to about 76 mg xanomeline tartrate, the ratio of the active ingredients in such a formulation is about 7.6 to 1.
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in powder form or in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, saline or sterile pyrogen-free water, immediately before use.
  • sterile liquid carrier for example, saline or sterile pyrogen-free water
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Formulations for parenteral administration include aqueous and non-aqueous (oily) sterile injection solutions of the active compounds which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions may take the form of tablets, lozenges, pastilles, or gels formulated in conventional manner.
  • Such compositions may comprise the active ingredient in a flavored basis such as sucrose and acacia or tragacanth.
  • the compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter, polyethylene glycol, or other glycerides.
  • Certain compounds disclosed herein may be administered topically, that is by non-systemic administration. This includes the application of a compound disclosed herein externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • systemic administration refers to oral, intravenous, intraperitoneal and intramuscular administration.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of inflammation such as gels, liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • the active ingredient for topical administration may comprise, for example, from 0.001% to 10% w/w (by weight) of the formulation. In certain embodiments, the active ingredient may comprise as much as 10% w/w. In other embodiments, it may comprise less than 5% w/w. In certain embodiments, the active ingredient may comprise from 2% w/w to 5% w/w. In other embodiments, it may comprise from 0.1% to 1% w/w of the formulation.
  • compounds may be conveniently delivered from an insufflator, nebulizer pressurized packs or other convenient means of delivering an aerosol spray.
  • Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds may be a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the powder composition may be presented in unit dosage form, in for example, capsules, cartridges, gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • Preferred unit dosage formulations are those containing an effective dose, as herein below recited, or an appropriate fraction thereof, of the active ingredient.
  • formulations described above may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavoring agents.
  • patients Before administering the claimed combinations, patients may have a lead-in period from one to fourteen days, during which lead-in period trospium chloride is given alone.
  • the trospium chloride is administered for one or more dose periods before administering xanomeline to accumulate trospium chloride in the body, or for the trospium chloride to reach or approach steady-state exposure levels. This accumulation, or higher exposure levels of the trospium chloride, increases the blockade of muscarinic receptors outside of the brain and reduces adverse events when xanomeline is administered.
  • the trospium chloride is administered for one or more days before xanomeline
  • animal models demonstrate the efficacy of new therapeutics for schizophrenia, including both pharmacological models (e.g., ketamine model) and genetic models (e.g., DISC1 mouse).
  • animal models including rodents, dogs and non-human primates demonstrate the side effect profile of pharmacological agents.
  • Animal models are an experimental proxy for humans but may suffer from deficiencies in the physiological differences between human and animals and thus may have limited predictive power for human experiments, particularly for central nervous system disorders.
  • the disclosed combination can be tried in controlled clinical trials of people. Standard measures based on patient self-report can be used by those skilled in the art to assess various side effects such as GI discomfort.
  • objective physiological measures e.g., EKGs
  • EKGs objective physiological measures
  • a set of standard measures has also been developed to assess schizophrenia symptoms including the Brief Psychiatric Rating Scale (BPRS), the Positive and Negative Syndrome Scale (PANSS), and Clinical Global Impression (CGI).
  • BPRS Brief Psychiatric Rating Scale
  • PANSS Positive and Negative Syndrome Scale
  • CGI Clinical Global Impression
  • the present disclosure also provides a medicament comprising a compound described herein and/or a salt thereof and at least one pharmaceutically acceptable carrier.
  • the medicament comprises between 5 mg and 300 mg of the compound, such as between 5 mg and 10 mg, between 10 mg and 15 mg, between 15 mg and 20 mg, between 20 mg and 25 mg, between 25 mg and 30 mg, between 30 mg and 35 mg, between 35 mg and 40 mg, between 40 mg and 45 mg, between 45 mg and 50 mg, between 50 mg and 55 mg, between 55 mg and 60 mg, between 60 mg and 65 mg, between 65 mg and 70 mg, between 70 mg and 75 mg, between 75 mg and 80 mg, between 80 mg and 85 mg, between 85 mg and 90 mg, between 90 mg and 95 mg, between 95 mg and 100 mg, between 100 mg and 105 mg, between 105 mg and 110 mg, between 110 mg and 115 mg, between 115 mg and 120 mg, between 120 mg and 125 mg, between 125 mg and 130 mg, between 130 mg and 135 mg, between 135 mg and 140 mg, between 140 mg and 145
  • the medicament further comprises a muscarinic inhibitor.
  • the muscarinic inhibitor is trospium chloride.
  • the medicament comprises between 5 mg and 150 mg of trospium chloride, such as between 5 mg and 10 mg, between 10 mg and 15 mg, between 15 mg and 20 mg, between 20 mg and 25 mg, between 25 mg and 30 mg, between 30 mg and 35 mg, between 35 mg and 40 mg, between 40 mg and 45 mg, between 45 mg and 50 mg, between 50 mg and 55 mg, between 55 mg and 60 mg, between 60 mg and 65 mg, between 65 mg and 70 mg, between 70 mg and 75 mg, between 75 mg and 80 mg, between 80 mg and 85 mg, between 85 mg and 90 mg, between 90 mg and 95 mg, between 95 mg and 100 mg, between 100 mg and 105 mg, between 105 mg and 110 mg, between 110 mg and 115 mg, between 115 mg and 120 mg, between 120 mg and 125 mg, between 125 mg and 130 mg, between 130 mg and 135 mg, between 135 mg and 140
  • the medicament is formulated as an immediate release formulation. In certain embodiments, the medicament is formulated as a controlled release formulation. In certain embodiments, the medicament is formulated as a controlled release formulation and the trospium chloride is formulated as an immediate release formulation.
  • the medicament comprises between 25 mg and 150 mg of the compound and between 10 mg and 40 mg trospium chloride in a single dosage form. In certain embodiments, the medicament comprises between 50 mg and 150 mg of the compound and between 10 mg and 40 mg trospium chloride in a single dosage form. In certain embodiments, the medicament comprises 50 milligrams of the compound. In certain embodiments, the medicament comprises 75 milligrams of the compound. In certain embodiments, the medicament comprises 10 milligrams trospium chloride. In certain embodiments, the medicament comprises 20 milligrams trospium chloride. In certain embodiments, the medicament is in the form of a single dosage formulation consisting essentially of 50 milligrams of the compound, 10 milligrams trospium chloride, and at least one pharmaceutically acceptable carrier.
  • the medicament is in the form of a single dosage formulation consisting essentially of 75 milligrams of the compound, 20 milligrams trospium chloride, and at least one pharmaceutically acceptable carrier. In certain embodiments, the medicament is in the form of a single dosage formulation consisting essentially of 50 milligrams of the compound, 20 milligrams trospium chloride, and at least one pharmaceutically acceptable carrier. In certain embodiments, the medicament is in the form of a single dosage formulation consisting essentially of 75 milligrams of the compound, 10 milligrams trospium chloride, and at least one pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutically acceptable carrier comprises cellulose and lactose.
  • the medicament is in the form of a single dosage formulation consisting essentially of 125 milligrams of the compound, 30 milligrams trospium chloride, and at least one pharmaceutically acceptable carrier. In certain embodiments, the medicament is in the form of a single dosage formulation consisting essentially of 100 milligrams of the compound, 20 milligrams trospium chloride, and at least one pharmaceutically acceptable carrier. In certain embodiments, the medicament is in the form of a single dosage formulation consisting essentially of 125 milligrams of the compound, 20 milligrams trospium chloride, and at least one pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutically acceptable carrier comprises cellulose and lactose.
  • patients Before administering the claimed combinations, patients may have a lead-in period from one to fourteen days, during which lead-in period trospium chloride is given alone.
  • the trospium chloride is administered for one or more dose periods before administering deuterated xanomeline to accumulate trospium chloride in the body, or for the trospium chloride to reach or approach steady-state exposure levels. This accumulation, or higher exposure levels of the trospium chloride, increases the blockade of muscarinic receptors outside of the brain and reduces adverse events when deuterated xanomeline is administered.
  • the trospium chloride is administered for one or more days before deuterated xanomeline.
  • deuterated xanomeline and trospium chloride are administered to a patient 6 times during a 24-hour period. In another embodiment, deuterated xanomeline and trospium chloride are administered to a patient 5 times during a 24-hour period. In another embodiment, deuterated xanomeline and trospium chloride are administered to a patient 4 times during a 24-hour period. In an embodiment, deuterated xanomeline and trospium chloride are administered to a patient 3 times during a 24-hour period. In another embodiment, deuterated xanomeline and trospium chloride are administered to a patient twice during a 24-hour period. In another embodiment, deuterated xanomeline and trospium chloride are administered to a patient once during a 24-hour period.
  • an extended release formulation of trospium chloride is used in combination with deuterated xanomeline.
  • trospium chloride extended release is administered to a patient from one time to five times during a 24-hour period.
  • trospium chloride extended release is administered from one to three times during a 24-hour period.
  • from five milligrams to 400 milligrams of trospium chloride extended release is used during a 24-hour period.
  • from 20 milligrams to 200 milligrams of trospium chloride extended release is used during a 24-hour period.
  • 250 mg deuterated xanomeline and 60 mg trospium chloride are administered to a patient in a 24-hour period. In one embodiment, 225 mg deuterated xanomeline and 60 mg trospium chloride are administered to a patient in a 24-hour period. In one embodiment, 225 mg deuterated xanomeline and 40 mg trospium chloride are administered to a patient in a 24-hour period. In another embodiment, 100 mg deuterated xanomeline and 20 mg trospium chloride are administered to a patient in a 24-hour period. In another embodiment, 125 mg deuterated xanomeline and 20 mg trospium chloride are administered to a patient in a 24-hour period.
  • 125 mg deuterated xanomeline and 30 mg trospium chloride are administered to a patient in a 24-hour period.
  • 125 mg deuterated xanomeline and 40 mg trospium chloride are administered to a patient in a 24-hour period.
  • 200 mg deuterated xanomeline and 40 mg trospium chloride are administered to a patient in a 24-hour period.
  • 200 mg deuterated xanomeline and 80 mg trospium chloride are administered to a patient in a 24-hour period.
  • 250 mg deuterated xanomeline and 60 mg trospium chloride are administered to a patient in a 24-hour period.
  • 250 mg deuterated xanomeline and 80 mg trospium chloride are administered to a patient in a 24-hour period.
  • 300 mg deuterated xanomeline and 40 mg trospium chloride are administered to a patient in a 24-hour period.
  • 300 mg deuterated xanomeline and 80 mg trospium chloride are administered to a patient in a 24-hour period.
  • 300 mg deuterated xanomeline and 120 mg trospium chloride are administered to a patient in a 24-hour period.
  • 300 mg deuterated xanomeline and 150 mg trospium chloride are administered to a patient in a 24-hour period.
  • 115 mg deuterated xanomeline and 40 mg trospium chloride are administered to a patient in a 24-hour period.
  • 50 mg deuterated xanomeline and 20 mg trospium chloride are administered to a patient in a 24-hour period.
  • 60 mg deuterated xanomeline and 20 mg trospium chloride are administered to a patient in a 24-hour period.
  • 60 mg deuterated xanomeline and 30 mg trospium chloride are administered to a patient in a 24-hour period.
  • 60 mg deuterated xanomeline and 40 mg trospium chloride are administered to a patient in a 24-hour period.
  • 100 mg deuterated xanomeline and 40 mg trospium chloride are administered to a patient in a 24-hour period.
  • 100 mg deuterated xanomeline and 80 mg trospium chloride are administered to a patient in a 24-hour period.
  • 125 mg deuterated xanomeline and 60 mg trospium chloride are administered to a patient in a 24-hour period.
  • 125 mg deuterated xanomeline and 80 mg trospium chloride are administered to a patient in a 24-hour period.
  • 150 mg deuterated xanomeline and 40 mg trospium chloride are administered to a patient in a 24-hour period.
  • 150 mg deuterated xanomeline and 80 mg trospium chloride are administered to a patient in a 24-hour period.
  • 150 mg deuterated xanomeline and 120 mg trospium chloride are administered to a patient in a 24-hour period.
  • 150 mg deuterated xanomeline and 150 mg trospium chloride are administered to a patient in a 24-hour period.
  • Treatment may be initiated with smaller dosages. Thereafter, the dosage may be increased by small increments until a balance between therapeutic effect and side effects is attained.
  • the health of the patient may be monitored by measuring one or more of the relevant indices at predetermined times during the treatment period. Treatment, including compound, amounts, times of administration and formulation, may be adjusted per such monitoring. The patient may be periodically reevaluated to determine improvement by measuring the same parameters. Adjustments to the disclosed compound administered and possibly to the time of administration may be made based on these reevaluations.
  • the single dosage form has a dosage strength of 50 mg deuterated xanomeline free base and 20 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 50 mg deuterated xanomeline free base and 10 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 75 mg deuterated xanomeline free base and 20 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 75 mg deuterated xanomeline free base and 10 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 125 mg deuterated xanomeline free base and 30 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 125 mg deuterated xanomeline free base and 40 mg trospium chloride.
  • the single dosage form has a dosage strength of 10 mg deuterated xanomeline and 30 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 10 mg deuterated xanomeline and 60 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 25 mg deuterated xanomeline and 30 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 25 mg deuterated xanomeline and 60 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 50 mg deuterated xanomeline and 30 mg trospium chloride.
  • the single dosage form has a dosage strength of 50 mg deuterated xanomeline and 60 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 100 mg deuterated xanomeline and 30 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 100 mg deuterated xanomeline and 60 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 125 mg deuterated xanomeline and 30 mg trospium chloride. In certain embodiments, the single dosage form has a dosage strength of 125 mg deuterated xanomeline and 60 mg trospium chloride.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the mode of administration.
  • the compounds can be administered in various modes, e.g. orally, topically, or by injection.
  • the precise amount of compound administered to a patient will be the responsibility of the attendant physician.
  • the specific dose level for any patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diets, time of administration, route of administration, rate of excretion, drug combination, the precise disorder being treated, and the severity of the indication or condition being treated. Also, the route of administration may vary depending on the condition and its severity.
  • the compounds described herein may be administered in combination with another therapeutic agent.
  • another therapeutic agent such as a pharmaceutically acceptable salt, ester, or prodrug thereof.
  • the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., by itself the adjuvant may only have minimal therapeutic benefit, but in combination with another therapeutic agent, the overall therapeutic benefit to the patient is enhanced).
  • the benefit of experienced by a patient may be increased by administering one of the compounds described herein with another therapeutic agent (which also includes a therapeutic regimen) that also has therapeutic benefit.
  • another therapeutic agent which also includes a therapeutic regimen
  • increased therapeutic benefit may result by also providing the patient with another therapeutic agent for diabetes.
  • the overall benefit experienced by the patient may simply be additive of the two therapeutic agents or the patient may experience a synergistic benefit.
  • the multiple therapeutic agents may be administered in any order or even simultaneously. If simultaneously, the multiple therapeutic agents may be provided in a single, unified form, or in multiple forms (by way of example only, either as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the timing between the multiple doses may be any duration of time ranging from a few min to four weeks.
  • the present disclosure further provides a method of treating a central nervous system disorder in a patient in need thereof, the method comprising administrating therapeutically effective amount of a compound described herein to the patient in need thereof.
  • the compound is orally administered.
  • musclecarinic disorder refers to any disease or condition ameliorated by activating the muscarinic system.
  • diseases include ones in which direct activation of muscarinic receptors themselves or inhibition of cholinesterase enzymes has produced a therapeutic effect.
  • disorders related to schizophrenia include, but are not limited to, schizo-affective disorder, psychosis, delusional disorders, psychosis associated with Alzheimer's disease, psychosis associated with Parkinson's disease, psychotic depression, bipolar disorder, bipolar with psychosis or any other disease with psychotic features.
  • movement disorders includes, but is not limited to, Gilles de la Tourette's syndrome, Friederich's ataxia, Huntington's chorea, restless leg syndrome and other diseases or disorders whose symptoms include excessive movements, ticks and spasms.
  • mamood disorders includes major depressive disorder, dysthymia, recurrent brief depression, minor depression disorder, bipolar disorder, mania and anxiety.
  • cognitive disorders refers to diseases or disorders marked by cognitive deficit (e.g., having abnormal working memory, problem solving abilities, etc.).
  • Diseases include but are not limited to Alzheimer's disease, Parkinson's Disease, dementia (including, but not limited to, AIDS related dementia, vascular dementia, age-related dementia, dementia associated with Lewy bodies and idiopathic dementia), Pick's disease, tauopathies, synucleinopathies, confusion, cognitive deficit associated with fatigue, learning disorders, traumatic brain injury, autism, age-related cognitive decline, and Cushing's Disease, a cognitive impairment associated with autoimmune diseases
  • ADHD attention deficit hyperactivity disorder
  • ADD attention deficit disorder
  • Dubowitz Syndrome FG Syndrome
  • IGF1 insulin-like growth factor I
  • addictive disorders refers to diseases or conditions marked by addiction or substance dependence as defined by the Diagnostic & Statistical Manual V (DSM-5). Such disorders are characterized by physical dependence, withdrawal and tolerance to a substance. Such substances include but are not limited to alcohol, cocaine, amphetamines, opioids, benzodiazepines, inhalants, nicotine, barbiturates, cocaine and cannabis. Addictive disorders also encompass behaviors that a patient does compulsively or continually despite clear negative consequences. For instance, ludomania (gambling addiction, or compulsive gambling) is recognized by those skilled in the art as being an addictive behavior that often has devastating consequences. In certain embodiments, the addictive behavior may be Internet Gaming Disorder (gaming addiction), as defined in the DSM-5.
  • DSM-5 Diagnostic & Statistical Manual V
  • Pain refers to physical suffering or discomfort caused by illness or injury. Pain is a subjective experience and the perception of pain is performed parts of the central nervous system (CNS). Usually noxious (peripheral) stimuli are transmitted to the CNS beforehand, but pain is not always associated with nociception. A broad variety of clinical pain exists, derived from different underlying pathophysiological mechanisms and needing different treatment approaches. Three major types of clinical pain have been characterized: acute pain, chronic pain, and neuropathic pain. In certain embodiments, deuterated xanomeline potently and effectively reverses tactile allodynia and heat hyperalgesia associated with established neuropathic and inflammatory pain in both rat and mouse models.
  • pain is treated, and the type of pain is chosen from allodynia, hyperalgesia, nociceptive pain, inflammatory pain, and neuropathic pain.
  • the pain is allodynia.
  • the pain is hyperalgesia.
  • the pain is nociceptive pain.
  • the pain is inflammatory pain.
  • the pain is neuropathic pain.
  • the central nervous system disorder is chosen from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, Lewy Body dementia, psychosis and cognition deficit.
  • the central nervous system disorder is schizophrenia.
  • the central nervous system disorder is Alzheimer's disease.
  • the central nervous system disorder is Huntington's disease.
  • the central nervous system disorder is Parkinson's disease.
  • the central nervous system disorder is Lewy Body dementia.
  • the central nervous system disorder is psychosis.
  • the central nervous system disorder is cognition deficit.
  • certain compounds and formulations disclosed herein may also be useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. Additional examples of animals include horses, dogs, and cats.
  • Scheme I depicts a general synthesis for installing a deuterated ether chain and/or a deuteromethyl group in xanomeline.
  • 3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole (1) was reacted in a Williamson ether synthesis with n-hexanol and sodium hydride in toluene to yield 3-(hexyloxy)-4-(pyridin-3-yl)-1,2,5-thiadiazole (2).
  • n-hexanol is substituted with a deuterated hexanol, (5′) to yield 3-((deutrohexyloxy)-4-(pyridin-3-yl)-1,2,5-thiadiazole (6′).
  • each R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 19 , R 20 , R 21 is independently chosen from H and D, and at least one of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 19 , R 20 , and R 21 is enriched with deuterium.
  • Each free base product can be converted to a pharmaceutically acceptable salt, such as the tartrate, using methods available in the art.
  • Scheme II depicts the synthesis for installing a perdeuterated ether chain and/or a trideuteromethyl group in xanomeline.
  • n-hexanol was substituted with a deuterated hexanol, such as perdeuterohexanol (1,1,2,2,3,3,4,4,5,5,6,6,6-hexanol-d 13 , 5) to yield 3-((hexyl-d 13 )oxy)-4-(pyridin-3-yl)-1,2,5-thiadiazole (6).
  • a deuterated hexanol such as perdeuterohexanol (1,1,2,2,3,3,4,4,5,5,6,6,6-hexanol-d 13 , 5)
  • alkyl esters of the compounds disclosed above which can be made by the methods above and may be useful as, inter alia, prodrugs.
  • Ethyl esters are shown, and other esters, such as methyl, n-propyl, isopropyl, and so on, are also provided herein.
  • the objective of this study was to assess the pharmacokinetics (PK) of xanomeline tartrate molecules (xanomeline, xanomeline-d 16 and xanomeline-d 13 ) following single oral dose administration of aqueous formulations to male Sprague-Dawley rats, as shown in Table 2.
  • PK pharmacokinetics
  • AUC 0-t , AUC 0-inf , C max , T max , and T 1/2 were calculated from the individual xanomeline, xanomeline-d 16 or xanomeline-d 13 plasma concentration data using standard noncompartmental methods, when possible.
  • the slopes of the elimination phase of the concentrations vs. time curve used to calculate the T 1/2 were determined by log-linear regression.
  • PK analyses were performed and validated using Phoenix® WinNonlin® version 8.0. To normalize the AUC across treatment groups, the xanomeline concentrations for each formulation was recalculated to account for bias, as shown in Table 3.
  • Xanomeline tartrate had a normalized AUC of 4210 h*pg/mg.
  • Xanomeline-d 13 had a normalized AUC of 8070 h*pg/mg and xanomeline-d 16 a normalized AUC of 6780 h*pg/mg ( FIG. 1 ).
  • the mean peak xanomeline, xanomeline-d 16 , and xanomeline-d 13 plasma concentrations were observed within 30 minutes post-dose independent of the treatment. Estimated elimination half-life (tr) was also similar among treatment groups (ranged between 1.5 and 2.7 hours post-dose).
  • Xanomeline levels following the oral administration of xanomeline tartrate 25 mg/kg were about mid-way between the levels of xanomeline-d 16 and xanomeline-d 13 obtained after administration of xanomeline-d 16 tartrate and xanomeline-d 13 tartrate at the same dosage.
  • Xanomeline-d 16 and xanomeline-d 13 were tested for their agonist capacity on FlpInTM Chinese hamster ovary (CHO) cells stably expressing the muscarinic acetylcholine receptor (mAChRs) human M1-M5 (hM1-hM5).
  • the Flp-InTM cell lines are designed for rapid generation of stable cell lines that express a protein of interest from a Flp-InTM expression vector. Targeted integration of a Flp-InTM expression vector ensured a high-level expression of the mAChRs hM1-hM5.
  • FIG. 2 units are expressed on the Y axis as counts per minute activity (CPMA) and then normalized to femtomoles per mg protein in FIG. 3 .
  • Extracellular signal-related kinase (ERK1/2 or p42/44) is a kinase in the mitogen-activated protein kinase (MAPK) family. Phosphorylation of ERK (pERK) can be used as a common end point measurement for the activation of many classes of G protein coupled receptors (GPCR) and beta-arrestin linked signaling.
  • GPCR G protein coupled receptors
  • FBS fetal bovine serum
  • values were normalized to the maximum FBS response. Nonlinear regression curves were calculated per the three parameters method with no constraints. Differences in drug potency were evaluated by comparing pEC 50 values and the differences in the compounds efficacy were analyzed by the maximal response (E max ). pEC50 values are listed at Table 4.
  • xanomeline-d 16 and xanomeline-d 13 were modestly potent partial agonists at mAChRs hM3>hM5>hM2, and were efficacious partial agonist at hM4>hM1.
  • These deuterated xanomeline derivatives have surprisingly low picomolar activity at M4 receptors. This activity is an order of magnitude greater than M1 receptors and several orders of magnitude greater than M2 receptors.
  • xanomeline-d 16 and xanomeline-d 13 have are selective for hM1 and hM4 over the other receptor subtypes.
  • Intact hepatocytes contain the cytochrome P450s (CYPs), other non-P450 enzymes, and phase II enzymes such as sulfo- and glucuronosyltransferases, and thus represent a prime model system for studying drug disposition in vitro.
  • CYPs cytochrome P450s
  • phase II enzymes such as sulfo- and glucuronosyltransferases
  • the incubation medium is prepared by combining a hepatocyte maintenance supplement pack (serum-free) with Williams Medium E and warmed to 37° C. in a water bath.
  • Compound stocks are prepared from test articles and positive controls dissolved in an organic solvent such as methanol or DMSO to desired concentration, such as 1 mM.
  • Hepatocytes are prepared immediately before assay, diluted to 1 ⁇ 10 6 viable cells/mL in Williams' Medium E supplemented with hepatocyte maintenance medium.
  • test compounds and positive controls are added and warmed with incubation medium to yield the desired working concentration.
  • a 2 ⁇ M solution is prepared by adding 10 ⁇ L of 1 mM test article stock solution to 5 mL incubation medium.
  • DMSO is a solvent
  • the concentration should not exceed 0.1%, with a maximum of 1% in the final incubation medium.
  • the test article is a deuterated xanomeline described herein.
  • positive controls include midazolam, phenacetin, testosterone, dextromethorphan, (S)-mephenytoin, and 7-hydroxycoumarin.
  • incubation medium containing the test article or positive control is pipetted into respective wells of a 12-well non-coated plate.
  • the final substrate concentration is 1 ⁇ M.
  • the plates are incubated on an orbital shaker to allow the substrates to warm for about 5-10 minutes before initiating reaction.
  • negative control 1.0 ⁇ 10 6 viable hepatocytes/mL are boiled for 5 minutes to eliminate enzymatic activity.
  • the 12-well non-coated plate containing the substrates is removed from the incubator. Reactions are started by adding 0.5 mL of 1.0 ⁇ 10 6 viable cells/mL in each well of the plate to yield a final cell density of 0.5 ⁇ 10 6 viable cells/mL. Next 0.5 mL of the inactivated hepatocytes are pipetted into the negative control wells. The plate is returned to the orbital shaker in the incubator and the shaker speed is adjusted to 90-120 rpm. Well contents are removed in 50- ⁇ L aliquots at 0, 15, 30, 60, 90 and 120 minutes. Additional time points 180 min and 240 min may be included but may not be necessary for healthy and metabolically competent hepatocytes to detect high turnover compounds. Incubations are stopped by adding sample aliquots (e.g. 50 ⁇ L) to tubes containing the appropriate quenching solvent and either freeze at ⁇ 70° C. or by direct extraction.
  • sample aliquots e.g. 50 ⁇ L
  • the cytochrome P 450 enzymes are expressed from the corresponding human cDNA using a baculovirus expression system (BD Biosciences, San Jose, Calif.).
  • Cytochrome P 450 Standard CYP1A2 Phenacetin CYP2A6 Coumarin CYP2B6 [ 13 C]-(S)-mephenytoin CYP2C8 Paclitaxel CYP2C9 Diclofenac CYP2C19 [ 13 C]-(S)-mephenytoin CYP2D6 (+/ ⁇ )-Bufuralol CYP2E1 Chlorzoxazone CYP3A4 Testosterone CYP4A [ 13 C]-Lauric acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
US17/310,735 2019-02-22 2020-02-21 Compounds and methods of deuterated xanomeline for treating neurological disorders Abandoned US20220144817A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/310,735 US20220144817A1 (en) 2019-02-22 2020-02-21 Compounds and methods of deuterated xanomeline for treating neurological disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962808954P 2019-02-22 2019-02-22
US201962936358P 2019-11-15 2019-11-15
US17/310,735 US20220144817A1 (en) 2019-02-22 2020-02-21 Compounds and methods of deuterated xanomeline for treating neurological disorders
PCT/US2020/019193 WO2020172516A1 (en) 2019-02-22 2020-02-21 Compounds and methods of deuterated xanomeline for treating neurological disorders

Publications (1)

Publication Number Publication Date
US20220144817A1 true US20220144817A1 (en) 2022-05-12

Family

ID=72145029

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/310,735 Abandoned US20220144817A1 (en) 2019-02-22 2020-02-21 Compounds and methods of deuterated xanomeline for treating neurological disorders

Country Status (8)

Country Link
US (1) US20220144817A1 (https=)
EP (1) EP3927342A4 (https=)
JP (1) JP2022523355A (https=)
CN (1) CN113507928A (https=)
AU (1) AU2020226870A1 (https=)
BR (1) BR112021016457A2 (https=)
CA (1) CA3131128A1 (https=)
WO (1) WO2020172516A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
US20240368149A1 (en) * 2023-04-24 2024-11-07 Terran Biosciences Inc. Analogs of xanomeline
WO2025174424A1 (en) * 2024-02-16 2025-08-21 Terran Biosciences Inc. Analogs of xanomeline, analogs of trospium, and methods of use thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115974863B (zh) * 2021-10-14 2024-12-31 南京迈诺威医药科技有限公司 占诺美林衍生物的苹果酸盐、a晶型及其制备方法和用途
CN119161338B (zh) * 2024-11-25 2025-06-17 嘉兴安帝康生物科技有限公司 用作毒蕈碱受体激动剂的四氢吡啶衍生物及其在医药上的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020556A1 (en) * 1995-12-07 1997-06-12 Eli Lilly And Company Method for treating pain

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508028A (ja) * 1994-10-31 1998-08-04 イーライ・リリー・アンド・カンパニー 不安を治療する方法
NZ542690A (en) * 2003-03-28 2009-04-30 Acadia Pharm Inc Muscarinic M1 receptor agonists for pain management
CA2754203A1 (en) * 2009-03-05 2010-09-10 Mithridion, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
US10265311B2 (en) * 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
PT3061821T (pt) * 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020556A1 (en) * 1995-12-07 1997-06-12 Eli Lilly And Company Method for treating pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Russak et al., Ann Pharmacother. Published August 23rd 2018 ;53(2):211-216 (Year: 2018) *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534434B2 (en) 2019-11-15 2022-12-27 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
US20240368149A1 (en) * 2023-04-24 2024-11-07 Terran Biosciences Inc. Analogs of xanomeline
US12269818B2 (en) * 2023-04-24 2025-04-08 Terran Biosciences Inc. Analogs of xanomeline
WO2025174424A1 (en) * 2024-02-16 2025-08-21 Terran Biosciences Inc. Analogs of xanomeline, analogs of trospium, and methods of use thereof

Also Published As

Publication number Publication date
JP2022523355A (ja) 2022-04-22
CA3131128A1 (en) 2020-08-27
EP3927342A1 (en) 2021-12-29
AU2020226870A1 (en) 2021-09-09
EP3927342A4 (en) 2022-11-16
BR112021016457A2 (pt) 2021-10-13
CN113507928A (zh) 2021-10-15
WO2020172516A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
US20220144817A1 (en) Compounds and methods of deuterated xanomeline for treating neurological disorders
US11951109B2 (en) EZH2 inhibitors for treating lymphoma
US11534434B2 (en) Xanomeline derivatives and methods for treating neurological disorders
US20100291026A1 (en) Piperidine inhibitors of janus kinase 3
JP2018048146A (ja) 免疫機能の２−オキソ−１，２−ジヒドロ−キノリン モジュレーター
CN102892770A (zh) 酪氨酸激酶三甲氧苯基抑制剂
US20100016365A1 (en) Substituted 4-amino-piperidines
CA2970948A1 (en) Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
US20100125094A1 (en) Pyrrolidinyl modulators of nicotinic acetylcholine receptors
US20110257260A1 (en) 3,4-methylenedioxyphenyl inhibitors of gaba aminotransferase and/or gaba reuptake transporter inhibitor
US20250179042A1 (en) Use of deuterated empathogens as therapeutic agents
WO2023049480A1 (en) Substituted phenylalkylamines
US20100075950A1 (en) Phenylpropanone modulators of dopamine receptor
CN116496205B (zh) 一种卡瑞斯汀的盐及其用途
WO2023034645A2 (en) Asymmetric allyl tryptamines
US20100120861A1 (en) Benzoic acid inhibitors of atp-sensitive potassium channels
US20100113478A1 (en) Indolone modulators of 5-ht3 receptor
EP2325169B1 (en) Lisofylline analogues and their pharmeacuetical uses
US20250034154A1 (en) Salts and solid forms of a compound that modulates irak4
US20180305298A1 (en) Deuterated chlorokynurenines for the treatment of neuropsychiatric disorders
MXPA06013484A (es) Metabolitos de (+)-(2s, 3s)-3-(2- metoxi-5- trifluorometoxibencilamino) -2-fenil- piperidina.
JPH08268949A (ja) ジフェニルメチレン誘導体

Legal Events

Date Code Title Description
AS Assignment

Owner name: KARUNA THERAPEUTICS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BENNETT, DENNIS;ATTARDO, GIORGIO;SCHLECHT, CLIFFORD;REEL/FRAME:057258/0617

Effective date: 20210820

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION